top of page
About Us
CEO Message
History
Contact Us
R&D
Core Technology
Publications
Pipeline
IMB001
IMB002
IR/PR
Notice
Press Release
Career
Recruitment Information
Talents
Employee Benefits
< Back
A new study by ImmunoBiome-POSTECH research team identifies new drug candidate targeting multiple sclerosis and inflammatory bowel disease
Microbiome Times
Previous
Next
bottom of page